Studies from Palacky University in the Area of Chronic Myeloid Leukemia Reported (Deep Molecular Response Achieved With Chemotherapy, Dasatinib and Interferon Alpha In Patients With Lymphoid Blast Crisis of Chronic Myeloid Leukaemia).

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      OLOMOUC (Czech Republic)
    • Abstract:
      Keywords: Olomouc; Czech Republic; Europe; Antineoplastics; BCR-ABL Tyrosine Kinase Inhibitors; Biological Factors; Cancer; Chemotherapy; Chronic Myeloid Leukemia; Cytokines; Dasatinib Therapy; Drugs and Therapies; Health and Medicine; Hematology; Intercellular Signaling Peptides and Proteins; Interferon Type I; Interferon-alpha; Interferons; Leukemia; Myeloid Leukemia; Oncology; Peptides; Pharmaceuticals; Proteins; Sprycel Therapy; Tyrosine Kinase Inhibitors EN Olomouc Czech Republic Europe Antineoplastics BCR-ABL Tyrosine Kinase Inhibitors Biological Factors Cancer Chemotherapy Chronic Myeloid Leukemia Cytokines Dasatinib Therapy Drugs and Therapies Health and Medicine Hematology Intercellular Signaling Peptides and Proteins Interferon Type I Interferon-alpha Interferons Leukemia Myeloid Leukemia Oncology Peptides Pharmaceuticals Proteins Sprycel Therapy Tyrosine Kinase Inhibitors 2389 2389 1 03/27/23 20230330 NES 230330 2023 MAR 31 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Current study results on Oncology - Chronic Myeloid Leukemia have been published. Keywords for this news article include: Olomouc, Czech Republic, Europe, Antineoplastics, BCR-ABL Tyrosine Kinase Inhibitors, Biological Factors, Cancer, Chemotherapy, Chronic Myeloid Leukemia, Cytokines, Dasatinib Therapy, Drugs and Therapies, Health and Medicine, Hematology, Intercellular Signaling Peptides and Proteins, Interferon Type I, Interferon-alpha, Interferons, Leukemia, Myeloid Leukemia, Oncology, Peptides, Pharmaceuticals, Proteins, Sprycel Therapy, Tyrosine Kinase Inhibitors, Palacky University. [Extracted from the article]
    • Abstract:
      Copyright of Hematology Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)